Interventions to reduce or prevent obesity in pregnant women: a systematic review

S Thangaratinam,1,2* E Rogozińska,1,3 K Jolly,4 S Glinkowski,3 W Duda,3 E Borowiack,3 T Roseboom,5 J Tomlinson,2 J Walczak,3 R Kunz,6 BW Mol,7 A Coomarasamy2 and KS Khan1

1Women’s Health Research Unit, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK
2School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
3Innovative Department, Arcana Institute, Krakow, Poland
4Department of Public Health, University of Birmingham, Birmingham, UK
5Clinical Epidemiology Biostatistics and Bioinformatics, Academic Medical Centre, Amsterdam, Netherlands
6Basel Institute for Clinical Epidemiology (BICE), University of Basel, Basel, Switzerland
7Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, Netherlands

*Corresponding author

Executive summary

Health Technology Assessment 2012; Vol. 16: No. 31
DOI: 10.3310/hta16310

Health Technology Assessment
NIHR HTA programme
www.hta.ac.uk
Executive summary

Background

The increasing prevalence of obesity is a major health problem: a recent Health Survey for England found that one-quarter of both men (23.6%) and women (23.8%) are obese, with a body mass index (BMI) of ≥ 30 kg/m². In total, 50% of women of childbearing age are either overweight (BMI 25–29.9 kg/m²) or obese, with 18% starting pregnancy as obese. Currently, 20–40% of women gain more than the recommended weight during pregnancy, resulting in an increased risk of maternal and fetal complications. More than half of women who die during pregnancy, childbirth or the puerperium are either obese or overweight. The maternal complications associated with obesity include miscarriage, hypertensive disorders such as pre-eclampsia, gestational diabetes mellitus, infection, thromboembolism, caesarean section, instrumental and traumatic deliveries, wound infection and endometritis. The fetal risks associated with obesity include stillbirths and neonatal deaths, macrosomia, neonatal unit admission, preterm births, congenital abnormalities and childhood obesity with associated long-term risks. Excessive weight gain in pregnancy is also associated with persistent retention of the weight gained beyond pregnancy in the mother and an increase in obesity in children at 2–4 years. The health risks to the mother and baby of obesity and excessive weight gain pose significant demands on the health-care system, with an increased need for additional care and resources in both primary and secondary care settings.

The antenatal period provides a window of opportunity to deliver weight management interventions as pregnant women are motivated to make changes and there are opportunities for regular contact with health professionals. Although reduction in weight gain or weight loss may be of benefit, there is a potential for harm to the mother or baby as a result of the weight loss itself or as a result of the interventions. The Institute of Medicine (IOM) guidelines describe the optimum weight gain in pregnancy for American women based on their BMI. The guidelines recommend a gestational weight gain of 11.5–16.0 kg in women with normal BMI (BMI 18.5–24.9 kg/m²), of 7.0–11.5 kg in overweight women (BMI 25–29.9 kg/m²) and of 5–9 kg in obese women (BMI ≥ 30 kg/m²). Current recommendations provide limited information on the magnitude of the benefits and adverse outcomes resulting from weight management in pregnancy.

Objectives

This health technology assessment (HTA) project was undertaken to evaluate the evidence on dietary and lifestyle interventions to reduce weight or prevent weight gain in pregnancy. The objectives were to:

- determine the effectiveness of various dietary and lifestyle interventions in pregnancy that prevent or treat obesity for maternal and fetal weight (primary objective)
- determine the effectiveness of various dietary and lifestyle interventions that prevent or treat obesity for obstetric antenatal, intrapartum and postnatal outcomes
- evaluate the benefit of the dietary and lifestyle weight management interventions in pregnancy for fetal and neonatal morbidity and mortality
study the potential short- and long-term adverse effects in mother and baby due to dietary
and lifestyle in pregnancy.

■ assess the overall strength of evidence across outcomes for effectiveness and harm
of interventions.

Methods

Systematic reviews of the effectiveness and harm of interventions were carried out using a
methodology in line with current recommendations. The following databases were searched
(1950 until March 2011) to identify relevant studies: MEDLINE, EMBASE, BIOSIS, Latin
American and Caribbean Health Sciences Literature (LILACS), Science Citation Index,
Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled
Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), HTA database and
PsycINFO. Relevant unpublished studies and those reported in the grey literature were searched
for in databases including Inside Conferences, Systems for Information in Grey Literature
(SIGLE), Dissertation Abstracts and ClinicalTrials.gov. Language restrictions were not applied.
The search strategy was developed by including search terms related to ‘pregnancy’ and ‘weight’.
The search was limited by filters for ‘human studies’ and ‘study type’ (randomised clinical trials
and observational trials exclusive of case series and case reports). We designed a separate search
strategy in the databases previously described to identify studies on harm by including adverse
effects text words and indexing terms to ensure that they were not missed. Study selection
was performed by two independent reviewers. First, the electronic searches were scrutinised
and full manuscripts of all citations that were likely to meet the predefined selection criteria
were obtained. Studies that met the predefined and explicit criteria regarding population,
interventions, outcomes and study design were selected for inclusion in the review.

Studies that evaluated any dietary, physical activity or behavioural counselling intervention with
the potential to influence weight change in pregnant women were included. Pregnant women
who were underweight (BMI < 18.5 kg/m²) were excluded. Both randomised controlled trials and
observational studies were included. For evaluation of adverse effects, in addition to these, case
series were included. The quality of the selected randomised controlled trials and observational
studies was assessed based on accepted contemporary standards. The risk of bias of the individual
randomised studies was assessed in six domains: sequence generation, allocation sequence
concealment, blinding, incomplete outcome data, selective outcome reporting and other potential
sources of bias. Results were summarised as pooled relative risks (RRs) with 95% confidence
intervals (CIs) for dichotomous data. Continuous data were summarised as mean difference
(MD) with 95% CIs. Separate analyses were performed on randomised and non-randomised
data. For meta-analysis of the data in the effectiveness review, non-randomised and observational
data were considered only if there was a paucity of randomised trial evidence for interpretation.
The chi-squared and $I^2$ statistics were used to assess statistical heterogeneity between trials. If
substantial heterogeneity was detected ($I^2 > 50\%$), possible causes were explored and subgroup
analyses for the main outcomes performed. Subgroups defined a priori were BMI of the women,
type of intervention, responders, publication year (last 20 years), study quality and setting.
Heterogeneity that was not explained by subgroup analyses was modelled using random-effects
analysis, where appropriate. Publication bias was assessed by funnel plots of the log-odds ratios.
All analysis was carried out using RevMan 5.0 statistical software (The Cochrane Collaboration,
The Nordic Cochrane Centre, Copenhagen, Denmark).

The relevant obstetric and neonatal outcomes considered to be important to decision-making
were identified by a two-round Delphi survey of clinicians. Gestational diabetes, pre-eclampsia,
thromboembolism and maternal admission to the high-dependency unit (HDU) or intensive care were considered to be the critically important clinical outcomes in the evaluation of interventions to prevent or reduce obesity in pregnancy. The critically important fetal outcomes were small-for-gestational-age fetuses, shoulder dystocia, intrauterine death, long-term neurological sequelae and admission to the neonatal intensive care unit. The quality of the overall evidence synthesised for each outcome was summarised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology and reported graphically as a two-dimensional chart.

**Results**

**Effectiveness of interventions**

**Study selection and identification**

From 19,583 citations, 88 full papers were selected for assessment of eligibility. A total of 56 experimental studies (40 randomised and 16 non-randomised controlled studies; involving 8842 women) and 32 observational studies (26 cohort and six case–control studies; involving 173,297 women) evaluated the effectiveness of dietary, physical activity and other lifestyle interventions in pregnancy for maternal and fetal outcomes.

**Quality of the included studies**

There was a low risk of bias for blinding for objective outcome assessments (38/40, 95%) and freedom from selective reporting (31/40, 77.5%). Four of the 40 randomised studies (10%) were blinded for subjective outcomes. Half of the studies adequately addressed the issue of incomplete outcome data (19/40). Sequence generation and allocation concealment were adequate in 40% (16/40) and 7.5% (3/40) of studies, respectively, and unclear in the others.

The quality of the included non-randomised studies varied from moderate to low. None of the 16 studies used blinding. More than 70% of the included cohort studies were adequate for representativeness, selection of the cohort, outcome assessment and follow-up. Of the case–control studies, case definition, representativeness, comparability and ascertainment of outcome were adequate in > 70%.

**Effect of interventions on weight-related outcomes**

A total of 30 randomised studies reported the effect of interventions on maternal weight and 28 the effect of interventions on fetal weight-related outcomes. Meta-analysis of the 30 studies (involving 4503 women) showed a overall reduction in weight gain in the intervention group of 0.97 kg compared with the control group (95% CI −1.60 kg to −0.34 kg; *p* = 0.003). This reduction in gestational weight gain was largest in the dietary intervention group, with a MD of −3.36 kg (95% CI −4.73 kg to −1.99 kg; *p* < 0.00001). There was a reduction trend in the number of women in the intervention group exceeding the IOM recommendations for weight gain in pregnancy (RR 0.77, 95% CI 0.42 to 1.42) and BMI at delivery (MD −0.23, 95% CI −1.4 to 0.94) for all interventions.

Meta-analysis of the 28 RCTs including 4573 babies showed a significant reduction in the pooled birthweight estimate of the infants in the intervention group, with a MD of −0.07 kg (95% CI −0.14 kg to −0.01 kg; *p* = 0.03) for all interventions. There was a 27% reduction (RR 0.73, 95% CI 0.54 to 0.99; *p* = 0.05) in the pooled estimate for the risk of large-for-gestational-age newborn (12 RCTs, involving 3021 newborns). There was no difference in the incidence of low-birthweight or small-for-gestational-age infants between the two groups, with a RR of 0.99 (95% CI 0.76 to 1.29). The studies were homogeneous. The effect was consistently observed with all interventions.
Effect of interventions on obstetric outcomes
A total of 29 randomised trials evaluated the effect of interventions in pregnancy on obstetric outcomes. Weight management interventions in pregnancy resulted in a significant overall reduction in the incidence of pre-eclampsia (RR 0.74, 95% CI 0.59 to 0.92; \( p = 0.008 \)) and shoulder dystocia (RR 0.39, 95% CI 0.22 to 0.70; \( p = 0.02 \)). The largest effect was observed with dietary interventions, with a significant decrease in pre-eclampsia (RR 0.67, 95% CI 0.53 to 0.85; \( p = 0.0009 \)) and gestational hypertension (RR 0.30, 95% CI 0.10 to 0.88; \( p = 0.03 \)). Dietary interventions in pregnancy also resulted in a significant reduction in preterm births (RR 0.68, 95% CI 0.48 to 0.96; \( p = 0.03 \)) and a trend towards a reduction in the incidence of gestational diabetes (RR 0.52, 95% CI 0.27 to 1.03). There were no overall differences in the rates of caesarean section (RR 0.93, 95% CI 0.85 to 1.03) or induction of labour (RR 1.12, 95% CI 1.00 to 1.26) between the groups for the interventions.

The mean gestational age of delivery was slightly reduced in the pooled estimate of all interventions, but was not statistically significant (MD –0.03 weeks, 95% CI –0.13 weeks to 0.07 weeks).

Effect of interventions on fetal and neonatal morbidity and mortality
Ten randomised studies (3375 babies) evaluated fetal and neonatal morbidity and mortality. There were no differences in the rates of admission to the neonatal intensive care unit, respiratory distress syndrome, neonatal hypoglycaemia, stillbirths and neonatal deaths or in Apgar scores at 1 minute and 5 minutes after delivery for all interventions. No differences were observed for stillbirths or perinatal deaths in the included non-randomised trials.

Adverse effects of interventions
A total of 26 studies involving 468,858 women were selected from 14,832 citations to evaluate the adverse effects of interventions. They included two randomised controlled trials and 24 observational studies (19 cohort and five case–control design).

Most of the data on adverse effects from dietary interventions were derived from studies on extreme diet and famine. There was an increase in the rate of neural tube defects and cleft lip and palate in pregnant women practising extreme forms of dieting and on high-glycaemic index diets. Starvation in pregnancy was associated with an increased incidence of metabolic syndrome, dyslipidaemia, coronary artery disease and hypertension. No significant maternal or fetal adverse effects of physical activity in pregnancy, such as cord abnormalities, threatened miscarriage, meconium-stained liquor, abnormal fetal heart rate pattern, maternal sepsis or chorioamnionitis, were observed.

Conclusions
Dietary and physical activity interventions in pregnancy are effective at reducing maternal weight gain in pregnancy (evidence quality was moderate) at birth compared with usual care. Typical dietary interventions include a balanced diet consisting of carbohydrates, proteins and fat and maintenance of a food diary. Typical physical activity-based interventions include light-intensity resistance training, weight-bearing exercises and walking for 30 minutes. They do not increase the risk of small-for-gestational-age or low-birthweight babies (evidence quality was high). Interventions that are mainly based on diet are effective at reducing obstetric outcomes such as gestational hypertension, pre-eclampsia, and shoulder dystocia and trend towards reduction in gestational diabetes (evidence quality was low to high). There were no changes in other neonatal morbidity or mortality outcomes with the interventions.
Implications for practice

The evidence is in favour of employing dietary interventions as opposed to other methods to reduce gestational weight gain in pregnancy and obstetric complications in both normal-weight and obese or overweight women. Mothers should be informed about the degree of benefit gained with weight management measures, especially diet, for various outcomes. Women can be reassured that there is no evidence of harm associated with the interventions to manage weight in pregnancy.

Recommendations for further research

Individual patient data meta-analyses will add value to the study-level data analysis reported here. There is a need for further research to identify the facilitators and barriers to the implementation of the interventions in various health-care settings. For interventions to be taken up by the women and provided by staff, the acceptability of the various components needs to be ascertained. If interventions are introduced on the basis of their effect on maternal weight change, there needs to be an evaluation alongside of their effects on other outcomes, as well as adverse outcomes. If randomised controlled trials are undertaken they should focus on clinically relevant outcomes.

[Note: The results of this systematic review for effectiveness of weight management interventions in pregnancy includes only studies published before March 2011. The findings with the updated search (until January 2012) can be accessed at BMJ 2012;344:e2088 doi10.1136/bmj.e2088.]

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke
Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?
Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

**Criteria for inclusion in the HTA journal series**

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors. Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 09/27/06. The contractual start date was in May 2010. The draft report began editorial review in June 2011 and was accepted for publication in November 2011. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley CBE

Series Editors: Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Peter Davidson, Dr Tom Marshall, Professor William McGuire, Professor John Powell, Dr Rob Riemsma, Professor Helen Snoooks and Professor Ken Stein

Editorial Contact: edit@southampton.ac.uk

© Queen’s Printer and Controller of HMSO 2012. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/).

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.

Printed on acid-free paper in the UK by Charlesworth Press.